Adaptive Pet Study
The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment. The information from the PET-CT may allow the investigators to change the radiation plan or the delivery of the radiation to the tumor/tumor site such as the total dose of radiation or the size of the area to receive further radiation. Presently the use of PET scans to adjust radiation therapy during radiation treatment is not standard of care and is being investigated in this study.
Checked against the public recordLast updated Apr 26, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Other
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Duke University
- Interventions being studied
- Other: PET-CT
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of carcinoma * Patients with local or regional nodal disease are eligible. * Zubrod Performance Status 0, 1, or 2. * Age ≥ 18 * Negative serum pregnancy test for women of child bearing potential * Patient must sign study-specific informed consent prior to study entry. Exclusion Criteria: * No gross disease visible on imaging at the start of radiotherapy * Contraindication to PET * Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy) * Breast feeding
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Duke University Medical CenterDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 26, 2023. Always confirm current availability with the study team.